Understand the source comparison
TB-4 Cardiac Health: Product Comparison
Precede comparison: This table compares TB-4 to related peptides investigated for cardiac repair mechanisms in preclinical and early clinical research. No peptide listed here is FDA-approved for cardiac indications as of 2026. | Peptide | Primary Mechanism | S
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Precede comparison: This table compares TB-4 to related peptides investigated for cardiac repair mechanisms in preclinical and early clinical research. No peptide listed here is FDA-approved for cardiac indications as of 2026.
- | Peptide | Primary Mechanism | Strongest Preclinical Evidence | Human Trial Status | Typical Research Dose | Stability Profile | Professional Assessment ||—|—|—|—|—|—|| TB-4 | Actin sequestration, VEGF upregulation, inflammatory modulation | 28% infarct size reduction in rodent LAD ligation models | Phase II complete (2014). No Phase III initiated | 6–42 mg/kg in animal models; 1.6 mg/kg bolus in human trial | Lyophilized: stable 24 months at −20°C; reconstituted: 14 days at 2–8°C | Most robust preclinical data for post-MI angiogenesis; limited human evidence || BPC-157 | Nitric oxide pathway activation, angiogenesis | Improved capillary density in ischemia-reperfusion models | No human cardiac trials published | 10 μg/kg in rodent models | Stable 18 months at −20°C; reconstituted: 30 days at 2–8°C | Angiogenic effects demonstrated but mechanism less defined than TB-4 || Thymalin | Thymic peptide, immune modulation, cytokine regulation | Reduced inflammatory markers in post-MI rat mod